Company intelligence / Profile preview

L&C BIO

Seongnam-si, Gyeonggi-do, South Korealncbio.co.kr ↗

Ownership: Private
Development stage: Other

Overview

L&C BIO has several commercialized products for infectious diseases and chronic conditions such as epilepsy and hypercholesterolemia. The company also has ongoing clinical trials for regenerative medicine products targeting cartilage repair in the knee and anti-adhesion barriers post-surgery. Notably:

MegaCarti® for cartilage regeneration in knee injuries—currently recruiting in multiple clinical studies.
MegaShield®–SP anti-adhesion barrier—recruiting for a confirmatory study after spine surgery[4].

Therapeutic areas: CardiovascularRheumatologyInfectious DiseasesNeurology
Modalities: Cell therapyBiologicSmall moleculeMedical device
Industry: Biotech

Drug pipeline

3 assets

Guardix-SP Plus

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on L&C BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L&C BIO.

Explore the full profile